Food and Drug Administration Update for Pediatric Practitioners.

New Dispensing Regulations Isotretinoin Regulations Implemented
Over the past year, new prescribing and dispensing regulations for isotretinoin (Accutane®) have been developed by the FDA and the drug’s business organisation, Roche Pharmaceuticals ( Pediatric Pharmacotherapy 2007).
On January 2, 2002, grooming materials on the SMART idea (System to Manage Accutane Teratogenicity) were distributed to eudaemonia care professionals.
This idea was developed to reduce the definite quantity of pregnancies occurring in women taking isotretinoin.
Prescriptions for Accutane® must now have a yellow dated fitness aculeus, provided by Roche to the prescriber, attached at the time the prescription drug is written.
This thorn ensures that the case has provided informed consent, is aware of the risks associated with therapy, and that animal patients have had the appropriate film pregnancy tests.
The mark date for full enforcement of the SMART platform is April 10, 2007.
After that date, only a 30-day Accutane® economic process may be dispensed.
Prescriptions for beast patients may only be filled within 7 days of the pricker making date.
This is a part of article Food and Drug Administration Update for Pediatric Practitioners. Taken from "Generic Isotretinoin Accutane" Information Blog